What is the recommended dose, duration, contraindications, and safety considerations for using tadalafil to treat benign prostatic hyperplasia (BPH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Tadalafil for Benign Prostatic Hyperplasia (BPH)

Tadalafil 5 mg once daily is an effective treatment option for men with lower urinary tract symptoms (LUTS) due to BPH, taken at approximately the same time each day regardless of sexual activity, and represents a particularly good choice for men who also have erectile dysfunction. 1, 2

Recommended Dose and Administration

The standard dose is tadalafil 5 mg once daily, taken at approximately the same time every day, without regard to timing of sexual activity or food intake 1, 2. This is the only FDA-approved dose for BPH treatment 2.

When Initiating BPH Therapy with Finasteride

  • Tadalafil 5 mg once daily can be combined with finasteride for up to 26 weeks
  • Beyond 26 weeks, the incremental benefit is unknown and this combination is not recommended long-term 2

Duration of Treatment

  • Symptom improvement begins as early as 2-4 weeks 3, 4
  • Studies demonstrate sustained efficacy through 12 weeks with maintained improvements up to 42 weeks 5
  • Long-term daily use is appropriate for ongoing symptom management 2

Efficacy Profile

Tadalafil 5 mg daily produces:

  • Mean IPSS reduction of approximately 4.8-5.6 points compared to 2.3-3.6 points with placebo 1, 2, 6
  • Improvements in both voiding (obstructive) and storage (irritative) symptoms 6, 3
  • Enhanced quality of life scores 6, 5
  • No significant improvement in peak urinary flow rate (Qmax), which distinguishes it from alpha-blockers 2, 3

The 2021 AUA guidelines note that while the absolute IPSS change is modest (-1.74 points difference from placebo), the percentage of treatment responders (≥3 point improvement) is significantly higher with tadalafil 1.

Contraindications

Absolute Contraindications

  • Concurrent use of nitrates in any form (nitroglycerin, isosorbide mononitrate/dinitrate) - this is life-threatening 2
  • Severe hepatic impairment (Child-Pugh Class C) 2

Relative Contraindications/Cautions

  • Severe renal impairment (CrCl <30 mL/min) or hemodialysis: Not recommended for once-daily use 2
  • Moderate renal impairment (CrCl 30-50 mL/min): Start with 2.5 mg daily, may increase to 5 mg based on response 2
  • Mild-moderate hepatic impairment (Child-Pugh Class A or B): Use with caution 2

Safety Considerations

Important Drug Interactions

  • Alpha-blockers: The combination of tadalafil 5 mg with alpha-blockers offers no advantage over either agent alone and increases side effects - this combination is NOT recommended 1
  • Antihypertensives: Monitor blood pressure, particularly in patients on multiple agents
  • CYP3A4 inhibitors: May increase tadalafil levels

Common Adverse Events

The drug is generally well-tolerated with discontinuation rates due to adverse events of approximately 1.79 times placebo 7. Common side effects include:

  • Headache
  • Dyspepsia
  • Back pain
  • Myalgia
  • Nasopharyngitis

Cardiovascular Safety

  • Safe in patients with cardiovascular disease including hypertension and ischemic heart disease when nitrates are not used 8
  • May actually improve endothelial function 8
  • No significant cardiovascular safety signals in clinical trials

Monitoring Requirements

  • Obtain baseline post-void residual (PVR) volume before initiating therapy
  • Monitor PVR at follow-up visits, as tadalafil may cause mild increases (approximately 25 mL) 1
  • Assess symptom response using IPSS at 4-12 week intervals

Clinical Decision-Making Algorithm

Choose tadalafil 5 mg daily when:

  1. Patient has moderate-to-severe LUTS (IPSS ≥8)
  2. Patient has concurrent erectile dysfunction (ideal scenario) 1
  3. Patient cannot tolerate or has contraindications to alpha-blockers
  4. Storage symptoms (frequency, urgency, nocturia) are prominent

Do NOT use tadalafil when:

  1. Patient is on nitrate therapy
  2. Patient has severe renal or hepatic impairment
  3. Considering combination with alpha-blockers (no added benefit, more side effects)

Key Clinical Pitfalls

  1. PSA monitoring: Unlike 5-alpha reductase inhibitors, tadalafil does not affect PSA levels - no adjustment needed
  2. Urinary retention risk: While generally safe, obtain baseline PVR and monitor, especially in patients with significant obstruction
  3. Age considerations: Younger patients may respond better to PDE5 inhibitors than older patients 9
  4. Expectation management: Tadalafil improves symptoms but does not improve objective flow rates - set appropriate patient expectations 1, 2
  5. Timing confusion: Unlike "as-needed" dosing for ED, BPH treatment requires consistent daily dosing regardless of sexual activity 2

Special Populations

Patients with both ED and BPH: Tadalafil 5 mg daily is particularly advantageous, addressing both conditions simultaneously 1, 2, 7

Diabetic patients: Demonstrated efficacy in men with type 1 or type 2 diabetes, though response may be slightly attenuated 2

Asian populations: Efficacy confirmed across multiple Asian studies with similar safety profile 5, 3, 4

References

Related Questions

Can I take tadalafil 20 mg daily for erectile dysfunction?
Should tadalafil (CIALIS) be discontinued in a patient with benign prostatic hyperplasia who presents with hematuria?
Is tadalafil (Cialis) 10 mg daily more effective than 5 mg daily for benign prostatic hyperplasia?
In a 71-year-old man with benign prostatic hyperplasia presenting with nocturia, weak urinary stream, mild PSA increase, hypertension, type 2 diabetes, hyperlipidemia, stage 3 chronic kidney disease on amlodipine, losartan, statin, and metformin, what is the recommended next step in management: start an alpha‑adrenergic blocker (tamsulosin) versus finasteride, oxybutynin, topical therapy, or referral for pelvic floor physical therapy?
In a 78-year-old male with benign prostatic hyperplasia who has a mild viral upper respiratory infection with postnasal drip, occasional cough with mildly green sputum, and rhinorrhea, is it appropriate to recommend an over-the-counter decongestant along with increased water intake, humidifier use, and saline nasal irrigation?
How should a floor‑of‑mouth mass be evaluated and managed?
What is the appropriate evaluation and management for a 25-year-old male who has lost 21 kg (from 66 kg to 45 kg)?
What is the recommended policy for using maternal blood for compatibility testing in neonates younger than six months?
What is the clinical significance of a NEWS2 score of 5 and what urgent management is recommended?
What is the standard BEP (bleomycin, etoposide, cisplatin) chemotherapy regimen, including dosing and schedule, for treating germ‑cell tumors?
What is the recommended BEP (Bleomycin, Etoposide, Cisplatin) chemotherapy regimen and supportive care?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.